Apogee Therapeutics (APGE) Net Cash Flow (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Net Cash Flow data on file, last reported at $320.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1018.24% year-over-year to $320.2 million in Q1 2026; TTM through Mar 2026 was $344.5 million, a 191.01% increase from a year earlier, with the FY2025 full-year figure at -$10.6 million, down 145.09% from the prior year.
• Net Cash Flow for Q1 2026 stood at $320.2 million, up from $23.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for APGE reached as high as $367.1 million in Q1 2024 and fell as low as -$188.5 million in Q3 2024.
• Historically, Net Cash Flow has averaged $46.0 million across 5 years, with a median of $4.8 million in 2022.
• Across the five-year window, Net Cash Flow jumped 6036.13% in 2023 and tumbled 1122.77% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $149.3 million in 2022, then plunged by 146.65% to -$69.7 million in 2023, then jumped by 133.03% to $23.0 million in 2024, then climbed by 2.5% to $23.6 million in 2025, then surged by 1257.72% to $320.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $320.2 million in Q1 2026, $23.6 million in Q4 2025, and -$16.6 million in Q3 2025.